The U.S. Food and Drug Administration has granted remote cardiac monitoring technology developer AliveCor marketing clearance for two new algorithms, giving users instant feedback on their electrocardiogram recordings and expanding its automated interpretation service offerings.

AliveCor’s new analysis processes (algorithms) include a normal detector that identifies when no abnormalities are detected in an ECG recording and an interference detector that identifies if factors have affected the recording, making the ECG unreadable.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access